Quince Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
70.6%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$1.48next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| LAM-001 Phase 2 SAPH Trial Initiation | 15 Nov 2026 |
| LAM-001 Phase 2 BOS Topline Data Release | 31 Mar 2027 |
Monitoring Framework
Key Performance Indicators
LAM-001 Phase 2b PH-ILD Trial Initiation QuarterlyTarget: Initiation in mid-2026
LAM-001 Phase 2 SAPH Trial Initiation QuarterlyTarget: Initiation in late-2026
Cash Runway AnnuallyTarget: Fund operations through the end of 2028
Watch Items
- LAM-001 Phase 2 BOS Topline DataTrigger: First Quarter of 2027Action: Evaluate efficacy and safety profile in bronchiolitis obliterans syndrome post lung transplant to determine advancement and trigger warrant exercises.
- LAM-001 Phase 2b PH-ILD Topline DataTrigger: First Quarter of 2028Action: Assess primary and secondary endpoints in pulmonary hypertension associated with interstitial lung disease to support potential registration pathways.
- Nasdaq Listing ComplianceTrigger: Minimum bid price and market value requirementsAction: Monitor Nasdaq listing compliance following the 1-for-10 reverse stock split implemented on April 10, 2026, and evaluate further reverse split authority (1-for-10 to 1-for-100) approved at the June 11, 2026 stockholder meeting if needed to maintain the minimum bid price.
Research as of 20 Jun 2026